Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient

Acta Haematol. 2022;145(2):210-213. doi: 10.1159/000519451. Epub 2021 Oct 6.


Vaccine-induced immune thrombotic thrombocytopenia (VITT) has already been described after vaccination with ChAdOx2 nCov-19 (AstraZeneca) and Ad26.COV2.S (Johnson & Johnson/Janssen). However, less knowledge so far has been gained about optimal therapeutic regimens in VITT-suspected patients. Here, we report the case of a 26-year-old female patient, who developed bilateral deep vein thrombosis in the lower legs and severe thrombocytopenia after ChAdOx2 nCov-19 vaccination. After initial anticoagulation therapy regimens including fondaparinux, apixaban, and danaparoid failed, the patient was successfully treated with high-dose intravenous immunoglobulins in combination with parental anticoagulation therapy with argatroban. As vaccination against severe acute respiratory syndrome coronavirus 2 affects billions of people worldwide, medical facilities and hospitals have to be prepared and provide effective treatment options in VITT-suspected patients, including rapid application of high-dose intravenous immunoglobulins, to improve patient outcomes.

Keywords: Severe acute respiratory syndrome coronavirus 2; Thrombocytopenia; Thrombosis; Vaccination; Vaccine-induced immune thrombotic thrombocytopenia.

Publication types

  • Case Reports

MeSH terms

  • Ad26COVS1
  • Adult
  • COVID-19 Vaccines / adverse effects
  • COVID-19*
  • Female
  • Humans
  • Thrombocytopenia*
  • Vaccines* / adverse effects


  • Ad26COVS1
  • COVID-19 Vaccines
  • Vaccines